PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis • PART 04: PIPELINE ANALYSIS • Pipeline analysis PART 05: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 06: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 07: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Immunotherapy - Market size and forecast 2018-2023 • Targeted therapy - Market size and forecast 2018-2023 • Market opportunity by type PART 08: CUSTOMER LANDSCAPE PART 09: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • Americas - Market size and forecast 2018-2023 • EMEA - Market size and forecast 2018-2023 • APAC - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Market trends PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • Bayer • Bristol-Myers Squibb • Eisai • Merck • Ono Pharmaceutical PART 14: APPENDIX • Research methodology • List of abbreviations   Exhibit 01: Years in consideration Exhibit 02: Global oncology therapeutics market Exhibit 03: Segments of global oncology therapeutics market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Late-stage pipeline drugs for liver cancer Exhibit 07: Market definition - Inclusions and exclusions checklist Exhibit 08: Market size 2018 Exhibit 09: Global market: Size and forecast 2018-2023 ($ billions) Exhibit 10: Global market: Year-over-year growth 2019-2023 (%) Exhibit 11: Five forces analysis 2018 Exhibit 12: Five forces analysis 2023 Exhibit 13: Bargaining power of buyers Exhibit 14: Bargaining power of suppliers Exhibit 15: Threat of new entrants Exhibit 16: Threat of substitutes Exhibit 17: Threat of rivalry Exhibit 18: Market condition - Five forces 2018 Exhibit 19: Type - Market share 2018-2023 (%) Exhibit 20: Comparison by type Exhibit 21: Immunotherapy - Market size and forecast 2018-2023 ($ billions) Exhibit 22: Immunotherapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Targeted therapy - Market size and forecast 2018-2023 ($ billions) Exhibit 24: Targeted therapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by type Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: Americas - Market size and forecast 2018-2023 ($ billions) Exhibit 30: Americas - Year-over-year growth 2019-2023 (%) Exhibit 31: EMEA - Market size and forecast 2018-2023 ($ billions) Exhibit 32: EMEA - Year-over-year growth 2019-2023 (%) Exhibit 33: APAC - Market size and forecast 2018-2023 ($ billions) Exhibit 34: APAC - Year-over-year growth 2019-2023 (%) Exhibit 35: Key leading countries Exhibit 36: Market opportunity Exhibit 37: Decision framework Exhibit 38: Impact of drivers and challenges Exhibit 39: Vendor landscape Exhibit 40: Landscape disruption Exhibit 41: Vendors covered Exhibit 42: Vendor classification Exhibit 43: Market positioning of vendors Exhibit 44: Bayer - Vendor overview Exhibit 45: Bayer - Business segments Exhibit 46: Bayer - Organizational developments Exhibit 47: Bayer - Geographic focus Exhibit 48: Bayer - Segment focus Exhibit 49: Bayer - Key offerings Exhibit 50: Bristol-Myers Squibb - Vendor overview Exhibit 51: Bristol-Myers Squibb - Business segments Exhibit 52: Bristol-Myers Squibb - Organizational developments Exhibit 53: Bristol-Myers Squibb - Geographic focus Exhibit 54: Bristol-Myers Squibb - Key offerings Exhibit 55: Eisai - Vendor overview Exhibit 56: Eisai - Business segments Exhibit 57: Eisai - Organizational developments Exhibit 58: Eisai - Geographic focus Exhibit 59: Eisai - Segment focus Exhibit 60: Eisai - Key offerings Exhibit 61: Merck - Vendor overview Exhibit 62: Merck - Business segments Exhibit 63: Merck - Organizational developments Exhibit 64: Merck - Geographic focus Exhibit 65: Merck - Segment focus Exhibit 66: Merck - Key offerings Exhibit 67: Ono Pharmaceutical - Vendor overview Exhibit 68: Ono Pharmaceutical - Business segments Exhibit 69: Ono Pharmaceutical - Organizational developments Exhibit 70: Ono Pharmaceutical - Geographic focus Exhibit 71: Ono Pharmaceutical - Key offerings Exhibit 72: Validation techniques employed for market sizing Exhibit 73: List of abbreviations    

Bayer Bristol-Myers Squibb Eisai Merck Ono Pharmaceutical